LenioBio GmbH
LenioBio GmbH develops scalable eukaryotic cell-free protein expression technologies enabling rapid and flexible production of complex proteins. Its proprietary platform facilitates expression of membrane proteins, antibodies, virus-like particles, and proteins with complex post-translational modifications, supporting applications from research to biomanufacturing and vaccine development. The technology addresses key bottlenecks in traditional protein production, offering fast turnaround, batch consistency, and the potential for integration with rapid DNA template synthesis. LenioBio collaborates with leading industry partners and continually advances its platform for broad accessibility and application in life sciences.
LenioBio GmbH
LenioBio GmbH, Merowingerplatz 1a, 40225 Dusseldorf, Germany
What We Do
Kit providing plant cell lysate for high-yield protein expression, supports complex post-translational modifications and up to 60 reactions.
Kit for small to mid-scale protein expression experiments, optimized for high yield and complex modifications.
Protein production kit designed for mg- to multi-gram scale using scalable plant cell lysate systems, supports up to 10 L scale with consistent yield.
Products and protocols designed for rapid antibody and protein candidate screening using cell-free systems, suitable for automation in high-throughput formats.
Service offerings for feasibility assessment, screening, development, and scalable production of research-grade proteins using cell-free technology.
Provides tailored protein production services using cell-free expression, covering cloning, optimization, expression, and purification for diverse targets, including membrane proteins and antibodies.
Application Area
Diagnostics
Digital Health Technologies
Key People
Chief Executive Officer
Chief Financial Officer
Chief Operating Officer
Chief Technology Officer
General Counsel
Head of R&D
News & Updates
Received the European Commission's STEP Seal as part of EU4Health funding, recognizing innovation and market value.
Awarded €2.37 million to accelerate scale-up of the cell-free protein expression platform.
Led consortium securing €2.75M to develop high-throughput glycoprotein production systems.
Describes how plant cell lysate-based cell-free expression technology enables rapid vaccine protein production, shortening lead times for outbreak response.
Demonstrates linear scaling of the cell-free platform to 10 L reaction volumes with consistent protein yields.
Provides guidance and discusses benefits when shifting protein production workflows from cell-based to cell-free systems.
Announced collaboration with Touchlight to integrate rapid enzymatic DNA synthesis with cell-free protein expression platforms for accelerated vaccine and therapeutic protein development, as part of a CEPI-funded initiative.
Engaged Avantor as a distribution partner to increase accessibility of cell-free protein expression solutions across Europe.
Appointed André Goerke as Chief Executive Officer, succeeding founder Dr. Remberto Martis.
Entered collaboration with ReciBioPharm to scale up cell-free protein expression to GMP-relevant and clinical-trial scale, as part of CEPI's 100 Days Mission.
Established strategic partnership with Labscoop to improve accessibility to cell-free protein expression technologies in North America.
Secured exclusive license agreement with Fraunhofer IME for vector and cryopreservation technology optimized for cell-free expression.